ResMed Inc. presented key updates at the JPM Healthcare Conference, highlighting its position as a global leader in connected and digital health. The company reported last twelve months $(LTM)$ revenue of $5.3 billion as of September 30, 2025, with operations spanning over 140 countries and a workforce of more than 10,000 employees. Revenue is generated primarily from devices, masks, and residential care software, with the majority of sales coming from the U.S., Canada, and Latin America. The presentation noted strong operating margins of 33% (GAAP) and 35% (Non-GAAP), along with a net cash position of $715 million in Q1 FY26. Free cash flow grew 31% year-over-year, reaching approximately $1.8 billion for the LTM Q1 FY26. ResMed emphasized the significant growth opportunities in underpenetrated markets for sleep apnea and related respiratory conditions, with less than 20% of patients diagnosed or treated in the U.S. and less than 10% internationally. The company outlined advances in digital health, including AI-enabled products and a network of more than 34 million patients on its AirView platform. Over 4.3 million diagnostic tests have been processed in the cloud, and the company’s residential care software network includes more than 170 million accounts. ResMed continues to invest in innovation and digital solutions to enhance patient care and clinical outcomes. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.
Comments